Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial
Authors' conclusion
To our knowledge, this is the first study measuring serum protein markers in the context of an intervention trial with baricitinib in patients with JIA.
Study context
- Population
- Children and adolescents (aged 2 to <18 years) with polyarticular juvenile idiopathic arthritis (JIA), extended oligoarticular JIA, enthesitis-related arthritis or juvenile PsA and inadequate response or intolerance to ≥1 csDMARD or bDMARD168 serum samples
- Participants
- 84 children
- Comparison
- Change in serum biomarkers from baseline to week 12 of baricitinib, by JIA-ACR response subset
- Non-respondersn = 10
- Respondersn = 27
- Super-respondersn = 47
Methodological detailsopen-label baricitinib 12-week lead-in period, parent trial: randomised, double-blind, placebo-controlled, withdrawal, phase 3, multicentre (75 centres in 20 countries), Olink Explore 3072 panel
- Open-label baricitinib 12-week lead-in period
- Parent trial: randomised, double-blind, placebo-controlled, withdrawal, phase 3
- Multicentre (75 centres in 20 countries)
- Olink Explore 3072 panel
Primary result
As reported in the abstract
Serum biomarker changes after 12 weeks of baricitinib · week 12
- Several serum biomarkers changed significantly in all patients, with higher magnitude changes in responders and super-responders
- Changes in macrophage activation markers (CCL7, CCL18, IL-6) and matrix metalloproteinase-3 positively correlated with clinical response
Original publication
Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial. Lancet Rheumatol. Published 4 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →